Le Wang

发表

Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.

Chang Park, John Xue, Saul H Rosenberg, 2007, Journal of medicinal chemistry.

Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.

Haiying Zhang, S. Rosenberg, N. Lin, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 4-[(3-methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor.

Haiying Zhang, N. Lin, H. Sham, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.

Haiying Zhang, N. Lin, H. Sham, 2003, Bioorganic & medicinal chemistry letters.

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.

L. Lam, Xin Lu, S. Rosenberg, 2017, Cancer research.

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

L. Lam, Chaohong Sun, S. Rosenberg, 2020, Nature.

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.

Chaohong Sun, L. Hasvold, Chang H. Park, 2017, Journal of Medicinal Chemistry.

Discovery of N-ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain.

K. Longenecker, P. Kovar, L. Hasvold, 2020, Journal of medicinal chemistry.

Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors.

Philip J. Merta, Magdalena Przytulinska, P. Kovar, 2008, Bioorganic & medicinal chemistry letters.

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

V. Stoll, T. Holzman, S. Muchmore, 2005, Anti-cancer drugs.

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Brian J. Smith, J. Baell, G. Nikolakopoulos, 2014, ACS medicinal chemistry letters.

Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.

Haiying Zhang, S. Rosenberg, N. Lin, 2003, Bioorganic & medicinal chemistry letters.

Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.

S. Rosenberg, R. B. Credo, H. Sham, 2002, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.

Chang Park, Philip J. Merta, Z. Tao, 2007, Journal of medicinal chemistry.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Dolores Diaz, Jun Chen, Deepak Sampath, 2015, Science Translational Medicine.

Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.

A. Petros, Chaohong Sun, P. Kovar, 2017, Journal of medicinal chemistry.

Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors.

R. Henry, Haiying Zhang, S. Rosenberg, 2004, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.

V. Stoll, Y. Tong, Haiying Zhang, 2004, Journal of medicinal chemistry.

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Brian J. Smith, C. Tse, A. Petros, 2014, ACS medicinal chemistry letters.

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor

Xiaohong Song, Z. Tao, P. Kovar, 2020, ACS medicinal chemistry letters.

Methylpyrrole inhibitors of BET bromodomains.

A. Petros, Chaohong Sun, N. Soni, 2017, Bioorganic & medicinal chemistry letters.

Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability.

V. Stoll, Y. Tong, Haiying Zhang, 2003, Bioorganic & medicinal chemistry letters.

Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.

A. Petros, P. Kovar, Chang H. Park, 2017, Journal of medicinal chemistry.

Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.

Ana L. Aguirre, A. Bogdan, Justin D Dietrich, 2018, Bioorganic & medicinal chemistry letters.

Methylpyrrole inhibitors of BET bromodomains.

A. Petros, N. Soni, P. Kovar, 2017, Bioorganic & medicinal chemistry letters.

Chang H. Park, D. Albert, Emily J. Faivre, 2017, Journal of medicinal chemistry.